Chemotherapy Induced Neutropenia Market Infographic
Chemotherapy Induced Neutropenia Market

Chemotherapy-Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. Some of the key Chemotherapy Induced Neutropenia symptoms include sore throat, sores in the mouth or toothache, abdominal pain, chills or sweating, and pain near the anus. The major factors contributing to the development of Chemotherapy-Induced neutropenia include older age, being female, poor performance status, bone marrow involvement, high LDH, low lymphocyte counts, high-risk chemotherapy regimen, and albumin level <3.5 G/Dl. 


Chemotherapy Induced Neutropenia Epidemiology Segmentation in the 7MM for the Study Period 2018-30


  • Total Number of Patients on Chemotherapy
  • Risk-Specific Chemotherapy Patient Pool for CIN
  • Total Incident Cases of CIN by Cancer Type


Chemotherapy Induced Neutropenia Epidemiology Insights Observed in 2020


  • The total number of cancer patients on chemotherapy in 7MM was observed to be 1,790,618.
  • The total number of cases of CIN in the 7MM was estimated to be 903,597.
  • The number of cases in the US was observed to be 383,339.
  • The cases of intermediate-high risk for CIN in the US was found to be 484,334.
  • The cases of low risk for CIN in the US was estimated to be 207,572.
  • The number of cancer patients on chemotherapy in the US was observed to be 691,906.
  • The cancer patients in chemotherapy in the EU5 countries and Japan was found to be 778,973 and 319,740, respectively.


Chemotherapy Induced Neutropenia Market Insights


Chemotherapy Induced Neutropenia Market is expected to grow at a CAGR of 1.76% in the 7MM for the study period (2018–2030).


Chemotherapy Induced Neutropenia Market Drivers


  • Robust pipeline
  • Rising incidence of cancer 
  • Rising awareness
  • Novel therapy development


Chemotherapy Induced Neutropenia Market Barriers


  • Patient compliance and disease burden
  • Diagnostic dilemma
  • Cost intensive treatment


Chemotherapy Induced Neutropenia Emerging Therapies 


The emerging drugs in the Chemotherapy Induced Neutropenia market are


  • Rolontis (eflapegrastim)
  • EC-18
  • ALRN-6924
  • CLT-008/Romyelocel-L
  • Myelo001
  • Plinabulin
  • F-627 (Ryzneuta), and many more


Chemotherapy Induced Neutropenia Market Prominent Players


The key companies in the Chemotherapy Induced Neutropenia market are


  • Spectrum Pharmaceuticals
  • Enzychem Lifesciences Corporation
  • Aileron Therapeutics
  • Cellerant Therapeutics
  • Myelo therapeutics
  • BeyondSpring Pharmaceuticals
  • Evive Biotech, and several others